SCHEDULE: Maverick Capital Discloses 7.8% Stake in Rocket Pharma

Maverick Capital and its affiliates have disclosed a passive beneficial ownership of 7.8% in Rocket Pharmaceuticals, Inc., totaling 8,363,813 shares.

Summary

• Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III collectively reported beneficial ownership of 8,363,813 shares of Rocket Pharmaceuticals, Inc. Common Stock.
• This ownership represents 7.8% of the outstanding Common Stock of Rocket Pharmaceuticals, Inc.
• The ownership percentage is based on 107,737,919 outstanding shares as of May 2, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 8, 2025.
• The shares are held for the accounts of Maverick's clients, including Maverick Fund USA, Ltd. (1,686,548 shares), Maverick Fund II, Ltd. (1,727,675 shares), Maverick Long Enhanced Fund, Ltd (1,930,078 shares), Maverick HP, L.P. (1,726,954 shares), Maverick Long Fund, Ltd. (958,547 shares), and certain separately managed accounts (334,011 shares).
• Maverick Capital, Ltd. is an investment adviser, and Maverick Capital Management is its General Partner, with Lee S. Ainslie III as the manager of Maverick Capital Management.
• The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable investment firm like Maverick Capital can be viewed as a vote of confidence in Rocket Pharmaceuticals, though it does not imply active management involvement or a change in control.

Positives

• A significant passive stake by a reputable institutional investor like Maverick Capital can signal confidence in Rocket Pharmaceuticals' long-term prospects.
• The disclosure of a substantial institutional holding may attract further investor interest and potentially improve market liquidity.

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor, indicating a significant passive stake in a publicly traded company. It does not provide specific industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may influence market perception and potentially the stock price, signaling institutional confidence.

Key Dates

Recommendation

The filing indicates a substantial passive investment by Maverick Capital, suggesting institutional confidence in Rocket Pharmaceuticals. However, as a Schedule 13G, it does not provide operational or financial performance details to warrant a stronger recommendation. Investors should consider this alongside other fundamental analysis.

Keywords

Rocket Pharmaceuticals, Maverick Capital, beneficial ownership, Schedule 13G, institutional investment, common stock